87 results on '"Ullmann, Andrew"'
Search Results
2. EFFICACY AND SAFETY OF CATHETER-DIRECTED THERAPY IN SUBMASSIVE PULMONARY EMBOLISM
3. Evolving epidemiology of pneumocystis pneumonia: Findings from a longitudinal population-based study and a retrospective multi-center study in Germany
4. A global public health convention for the 21st century
5. Onkologie und Ökonomie – wie frei sind wir wirklich in der Behandlung von Patient*innen?
6. Erratum zu: Impfen bei Immundefizienz
7. In Vitro Evaluation of Radiolabeled Amphotericin B for Molecular Imaging of Mold Infections
8. Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
9. Impfen bei Immundefizienz
10. Impact of immunosuppressive and antifungal drugs on PBMC- and whole blood-based flow cytometric CD154+ Aspergillus fumigatus specific T-cell quantification
11. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
12. Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT
13. Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells
14. Comparative Analysis of Inflammatory Cytokine Release and Alveolar Epithelial Barrier Invasion in a Transwell® Bilayer Model of Mucormycosis
15. Evaluation of Aspergillus and Mucorales specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure
16. Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO)
17. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole
18. Susceptibility ofA. fumigatus-specific T-cell assays to pre-analytic blood storage and PBMC cryopreservation greatly depends on readout platform and analytes
19. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
20. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
21. Analysis of the in vitro activity of human neutrophils against Aspergillus fumigatus in presence of antifungal and immunosuppressive agents
22. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease
23. Invasive Pilzinfektionen: Nonresponder und Durchbruchinfektionen unter antimykotischer Medikation
24. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease
25. Intra- and inter-individual variability ofAspergillus fumigatusreactive T-cell frequencies in healthy volunteers in dependency of mould exposure in residential and working environment
26. Mucorales spores induce a proinflammatory cytokine response in human mononuclear phagocytes and harbor no rodlet hydrophobins
27. Screening and contact precautions – A survey on infection control measures for multidrug-resistant bacteria in German university hospitals
28. The “Choosing Wisely” initiative in infectious diseases
29. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study
30. Position paper on current aspects of sponsoring in accredited CME
31. Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients
32. Clinical evidence for caspofungin monotherapy in the first‐line and salvage therapy of invasive Aspergillus infections
33. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
34. Hepatic Safety of Isavuconazole Compared With Voriconazole in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Complicated by Invasive Mold Disease: A Post-Hoc Analysis From the SECURE Study
35. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
36. Clinical-scale isolation of the total Aspergillus fumigatus–reactive T–helper cell repertoire for adoptive transfer
37. Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study
38. Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease
39. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology
40. Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
41. Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
42. Efficacy of micafungin in invasive candidiasis caused by commonCandidaspecies with special emphasis on non-albicans Candidaspecies
43. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
44. Safety of micafungin in prospective and retrospective clinical trials
45. Particular Characteristics of Encapsulated Bacteria
46. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease
47. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases
48. Tool for Guidance: Evidence-Based Recommendations for Managing Febrile Neutropenia
49. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWP01 trial
50. Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.